Canadian Imperial Bank of Commerce (CIBC) has filed a preliminary pricing supplement for its new senior global medium-term notes, a strategic move aimed at diversifying its funding sources. This filing, dated November 10, 2026, is significant as it reflects the bank's efforts to enhance its capital structure in a competitive commercial banking environment.
CIBC, listed on the NYSE under the ticker CM and on the OTC under CNDIF, operates within the Commercial Banks, NEC sector (SIC 6029). The bank has been active in the capital markets, with a series of recent filings indicating its commitment to raising funds through various instruments.
What the Filing Says
The filing outlines the terms of the new notes, which are linked to the MSCI EAFE Index. Notably, these notes do not bear interest, and their return at maturity will depend on the performance of the index. Investors will receive a cash amount based on the index's performance, with a potential upside participation rate of 1.6 times the index return, subject to a maximum settlement amount.
The notes have complex features and investing in the notes involves risks not associated with an investment in conventional debt securities.
The notes are unsecured obligations of CIBC and will not constitute deposits insured by any government agency. This raises the credit risk associated with these notes, a factor that potential investors must consider.
Impact
This filing may affect a range of stakeholders, including current and potential investors in CIBC's debt securities. The unique structure of the notes, along with their linkage to the MSCI EAFE Index, may attract interest from investors looking for exposure to international equity markets.
What's Next
Details regarding the next steps following this filing were not available in the SEC filing. Investors and market participants will be watching for further announcements from CIBC regarding the issuance and performance of these notes.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










